These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 22738896

  • 1. Insight into new potential targets for the treatment of overactive bladder and detrusor overactivity.
    Cerruto MA, Asimakopoulos AD, Artibani W, Del Popolo G, La Martina M, Carone R, Finazzi-Agrò E.
    Urol Int; 2012; 89(1):1-8. PubMed ID: 22738896
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Developments in the pharmacotherapy of the overactive bladder.
    Sellers DJ, McKay N.
    Curr Opin Urol; 2007 Jul; 17(4):223-30. PubMed ID: 17558263
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic receptor targets for lower urinary tract dysfunction.
    Yoshimura N, Kaiho Y, Miyazato M, Yunoki T, Tai C, Chancellor MB, Tyagi P.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):437-48. PubMed ID: 18034230
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology and pharmacotherapy of overactive bladder.
    Yoshida M, Masunaga K, Nagata T, Yono M, Homma Y.
    J Pharmacol Sci; 2010 Jun; 112(2):128-34. PubMed ID: 20134115
    [Abstract] [Full Text] [Related]

  • 11. Muscarinic receptor antagonists for overactive bladder.
    Abrams P, Andersson KE.
    BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
    [Abstract] [Full Text] [Related]

  • 12. Antimuscarinic mechanisms and the overactive detrusor: an update.
    Andersson KE.
    Eur Urol; 2011 Mar; 59(3):377-86. PubMed ID: 21168951
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological and genetic analysis of mechanisms underlying detrusor overactivity in rats.
    Yokoyama O.
    Neurourol Urodyn; 2010 Mar; 29(1):107-11. PubMed ID: 20025014
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Potential Future Pharmacological Treatment of Bladder Dysfunction.
    Andersson KE.
    Basic Clin Pharmacol Toxicol; 2016 Oct; 119 Suppl 3():75-85. PubMed ID: 26990140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.